DPP-4 inhibitors can inhibit glucagon secretion by increasing endogenous GLP-1 in patients and can be used in combination with insulin to improve insulin resistance, eliminate hyperglycemic toxicity altogether, complement the mechanism, and control glucose for a long time. This evidence concerns the gene GCG and Insulin resistance.